Heron Therapeutics Inc (NASDAQ:HRTX) Receives $58.00 Consensus Target Price from Brokerages

Share on StockTwits

Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have been given a consensus rating of “Hold” by the nine ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $58.00.

Several equities research analysts recently commented on HRTX shares. Cowen restated a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, May 9th. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. Northland Securities restated a “buy” rating and set a $55.00 target price on shares of Heron Therapeutics in a research report on Monday, August 5th. Evercore ISI restated a “buy” rating and set a $75.00 target price on shares of Heron Therapeutics in a research report on Tuesday, August 13th. Finally, Stifel Nicolaus restated a “buy” rating and set a $38.00 target price on shares of Heron Therapeutics in a research report on Monday, August 5th.

Shares of NASDAQ HRTX traded down $0.71 during trading on Friday, reaching $17.38. The company had a trading volume of 441,401 shares, compared to its average volume of 861,797. The company’s fifty day moving average price is $17.86 and its 200-day moving average price is $21.15. Heron Therapeutics has a 12 month low of $15.68 and a 12 month high of $41.10. The stock has a market cap of $1.44 billion, a P/E ratio of -7.12 and a beta of 1.49. The company has a quick ratio of 3.70, a current ratio of 4.01 and a debt-to-equity ratio of 0.04.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02. Heron Therapeutics had a negative return on equity of 56.89% and a negative net margin of 172.07%. The firm had revenue of $36.66 million for the quarter, compared to analyst estimates of $31.04 million. As a group, equities analysts predict that Heron Therapeutics will post -2.73 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the stock. Meadow Creek Investment Management LLC bought a new position in Heron Therapeutics in the second quarter worth approximately $27,000. Lindbrook Capital LLC bought a new position in Heron Therapeutics in the second quarter worth approximately $37,000. Parallel Advisors LLC raised its stake in shares of Heron Therapeutics by 247.4% in the first quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 1,200 shares during the last quarter. Pearl River Capital LLC raised its stake in shares of Heron Therapeutics by 1,900.0% in the first quarter. Pearl River Capital LLC now owns 2,000 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,900 shares during the last quarter. Finally, US Bancorp DE raised its stake in shares of Heron Therapeutics by 75.6% in the second quarter. US Bancorp DE now owns 4,108 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 1,769 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: What is an overbought condition?

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Prudential Financial Inc. Has $1.97 Million Stock Position in PC Connection, Inc.
Prudential Financial Inc. Has $1.97 Million Stock Position in PC Connection, Inc.
Wells Fargo & Company MN Decreases Stock Holdings in Invesco Value Municipal Income Trust
Wells Fargo & Company MN Decreases Stock Holdings in Invesco Value Municipal Income Trust
Intelsat SA  Shares Sold by Wells Fargo & Company MN
Intelsat SA Shares Sold by Wells Fargo & Company MN
Wells Fargo & Company MN Purchases 2,960 Shares of Vectrus Inc
Wells Fargo & Company MN Purchases 2,960 Shares of Vectrus Inc
NumerixS Investment Technologies Inc Acquires Shares of 1,100 NextEra Energy Inc
NumerixS Investment Technologies Inc Acquires Shares of 1,100 NextEra Energy Inc
FedEx  Shares Gap Down  After Analyst Downgrade
FedEx Shares Gap Down After Analyst Downgrade


 
© 2006-2019 Zolmax.